Compare Wockhardt with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs IPCA LABS - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT IPCA LABS WOCKHARDT/
IPCA LABS
 
P/E (TTM) x -18.6 21.3 - View Chart
P/BV x 1.0 4.1 23.8% View Chart
Dividend Yield % 0.0 0.1 3.4%  

Financials

 WOCKHARDT   IPCA LABS
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
IPCA LABS
Mar-18
WOCKHARDT/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,012695 145.5%   
Low Rs532400 132.9%   
Sales per share (Unadj.) Rs355.9260.2 136.8%  
Earnings per share (Unadj.) Rs-60.319.0 -317.7%  
Cash flow per share (Unadj.) Rs-46.833.1 -141.5%  
Dividends per share (Unadj.) Rs0.011.00 1.0%  
Dividend yield (eoy) %00.2 0.7%  
Book value per share (Unadj.) Rs257.8213.0 121.0%  
Shares outstanding (eoy) m110.63126.20 87.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.22.1 103.0%   
Avg P/E ratio x-12.828.9 -44.3%  
P/CF ratio (eoy) x-16.516.6 -99.6%  
Price / Book Value ratio x3.02.6 116.4%  
Dividend payout %05.3 -0.3%   
Avg Mkt Cap Rs m85,37969,120 123.5%   
No. of employees `0006.313.3 47.2%   
Total wages/salary Rs m9,3717,359 127.3%   
Avg. sales/employee Rs Th6,295.02,477.4 254.1%   
Avg. wages/employee Rs Th1,498.3555.2 269.9%   
Avg. net profit/employee Rs Th-1,066.3180.6 -590.3%   
INCOME DATA
Net Sales Rs m39,36932,836 119.9%  
Other income Rs m1,202418 287.6%   
Total revenues Rs m40,57133,254 122.0%   
Gross profit Rs m184,505 0.4%  
Depreciation Rs m1,4951,777 84.1%   
Interest Rs m2,555240 1,063.7%   
Profit before tax Rs m-2,8302,905 -97.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m257511 50.3%   
Profit after tax Rs m-6,6692,394 -278.5%  
Gross profit margin %013.7 0.3%  
Effective tax rate %-9.117.6 -51.6%   
Net profit margin %-16.97.3 -232.3%  
BALANCE SHEET DATA
Current assets Rs m33,79619,455 173.7%   
Current liabilities Rs m26,91710,076 267.1%   
Net working cap to sales %17.528.6 61.2%  
Current ratio x1.31.9 65.0%  
Inventory Days Days7998 81.0%  
Debtors Days Days8967 133.3%  
Net fixed assets Rs m39,66420,260 195.8%   
Share capital Rs m553252 219.2%   
"Free" reserves Rs m27,96826,633 105.0%   
Net worth Rs m28,52226,886 106.1%   
Long term debt Rs m21,7312,340 928.6%   
Total assets Rs m81,62041,173 198.2%  
Interest coverage x-0.113.1 -0.8%   
Debt to equity ratio x0.80.1 875.4%  
Sales to assets ratio x0.50.8 60.5%   
Return on assets %-5.06.4 -78.8%  
Return on equity %-23.48.9 -262.6%  
Return on capital %-7.710.8 -71.3%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m9,80715,642 62.7%   
Fx outflow Rs m1,7894,884 36.6%   
Net fx Rs m8,01910,759 74.5%   
CASH FLOW
From Operations Rs m6843,411 20.1%  
From Investments Rs m6,302-1,354 -465.5%  
From Financial Activity Rs m-7,695-1,304 590.0%  
Net Cashflow Rs m-664753 -88.2%  

Share Holding

Indian Promoters % 74.5 45.9 162.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 11.4 20.2%  
FIIs % 7.7 25.3 30.4%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 17.4 88.5%  
Shareholders   67,757 36,892 183.7%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   PLETHICO PHARMA  BIOCON   UNICHEM LAB  ALKEM LABORATORIES  AJANTA PHARMA  

Compare WOCKHARDT With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Higher; Energy & Realty Stocks Lead(09:30 am)

Asian share markets are higher today as Britain and the EU made headway on a Brexit deal ahead of a leaders' summit.

Related Views on News

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Oct 16, 2019 10:37 AM

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WOCKHARDT - WYETH LTD COMPARISON

COMPARE WOCKHARDT WITH

MARKET STATS